HRP20161619T1 - Terapijske primjene eslikarbazepina - Google Patents
Terapijske primjene eslikarbazepina Download PDFInfo
- Publication number
- HRP20161619T1 HRP20161619T1 HRP20161619TT HRP20161619T HRP20161619T1 HR P20161619 T1 HRP20161619 T1 HR P20161619T1 HR P20161619T T HRP20161619T T HR P20161619TT HR P20161619 T HRP20161619 T HR P20161619T HR P20161619 T1 HRP20161619 T1 HR P20161619T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- glycoprotein
- drug
- substrate
- eslicarbazepine
- Prior art date
Links
- BMPDWHIDQYTSHX-AWEZNQCLSA-N (S)-MHD Chemical compound C1[C@H](O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-AWEZNQCLSA-N 0.000 title claims 4
- 229960004028 eslicarbazepine Drugs 0.000 title claims 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims 8
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 239000000758 substrate Substances 0.000 claims 7
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical compound CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 claims 3
- 229960003233 eslicarbazepine acetate Drugs 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims 1
- 102000014842 Multidrug resistance proteins Human genes 0.000 claims 1
- 108050005144 Multidrug resistance proteins Proteins 0.000 claims 1
- 229940049937 Pgp inhibitor Drugs 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003472 felbamate Drugs 0.000 claims 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims 1
- 239000002748 glycoprotein P inhibitor Substances 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 229960001816 oxcarbazepine Drugs 0.000 claims 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims 1
- 229960002695 phenobarbital Drugs 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 229940121649 protein inhibitor Drugs 0.000 claims 1
- 239000012268 protein inhibitor Substances 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Upotreba eslikarbazepina ili eslikarbazepin acetata naznačena time da je za proizvodnju lijeka za liječenje stanja intraktabilne epilepsije u okolnostima kada je bolesnik kojeg treba liječiti prethodno liječen od epilepsije s lijekom koji je supstrat za P-glikoprotein ili proteine višestruke rezistencije.
2. Upotreba prema zahtjevu 1, naznačena time da da se eslikarbazepin ili eslikarbazepin acetat primjenjuje kao monoterapija za liječenje navedenog stanja.
3. Upotreba prema zahtjevu 1 ili zahtjevu 2, naznačena time da se eslikarbazepin ili eslikarbazepin acetat primjenjuje u nedostatku inhibitora P-glikoproteina ili inhibitora proteina višestruke rezistencije.
4. Upotreba prema bilo kojem prethodnom zahtjevu, naznačena time da stanje je refraktorno stanje.
5. Upotreba prema zahtjevu 4, naznačena time da refraktorno stanje poremećaja je zbog prekomjerne ekspresije P-glikoproteina i/ili proteina višestruke rezistencije.
6. Upotreba prema bilo kojem od zahtjeva 1 do 3, naznačena time da intraktabilno stanje je farmakorezistentno stanje.
7. Upotreba prema zahtjevu 1, naznačena time da lijek koji je supstrat za P-glikoprotein ili proteine višestruke rezistencije je fenitoin.
8. Upotreba prema zahtjevu 1, naznačena time da lijek koji je supstrat za P-glikoprotein ili proteine višestruke rezistencije je fenobarbital.
9. Upotreba prema zahtjevu 1, naznačena time da lijek koji je supstrat za P-glikoprotein ili proteine višestruke rezistencije je karbamazepin.
10. Upotreba prema zahtjevu 1, naznačena time da lijek koji je supstrat za P-glikoprotein ili proteine višestruke rezistencije je okskarbazepin.
11. Upotreba prema zahtjevu 1, naznačena time da lijek koji je supstrat za P-glikoprotein ili proteine višestruke rezistencije je felbamat.
12. Upotreba prema zahtjevu 1, naznačena time da lijek koji je supstrat za P-glikoprotein ili proteine višestruke rezistencije je lamotrigin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0700773.5A GB0700773D0 (en) | 2007-01-15 | 2007-01-15 | Drug therapies |
| PCT/PT2008/000002 WO2008088233A1 (en) | 2007-01-15 | 2008-01-14 | Therapeutical uses of eslicarbazepine |
| EP08705172.8A EP2121138B1 (en) | 2007-01-15 | 2008-01-14 | Therapeutical uses of eslicarbazepine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161619T1 true HRP20161619T1 (hr) | 2017-01-13 |
Family
ID=37809995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161619TT HRP20161619T1 (hr) | 2007-01-15 | 2016-12-02 | Terapijske primjene eslikarbazepina |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20100048538A1 (hr) |
| EP (2) | EP3222323A1 (hr) |
| JP (1) | JP2010515727A (hr) |
| KR (1) | KR101519040B1 (hr) |
| CN (1) | CN101605571A (hr) |
| AR (1) | AR064898A1 (hr) |
| AU (1) | AU2008205712B2 (hr) |
| BR (1) | BRPI0806568A2 (hr) |
| CA (1) | CA2674303C (hr) |
| CY (1) | CY1118297T1 (hr) |
| DK (1) | DK2121138T3 (hr) |
| ES (1) | ES2606952T3 (hr) |
| GB (1) | GB0700773D0 (hr) |
| HR (1) | HRP20161619T1 (hr) |
| HU (1) | HUE032467T2 (hr) |
| IL (1) | IL199697A0 (hr) |
| LT (1) | LT2121138T (hr) |
| MX (1) | MX2009007486A (hr) |
| NZ (1) | NZ578331A (hr) |
| PL (1) | PL2121138T3 (hr) |
| PT (1) | PT2121138T (hr) |
| RS (1) | RS55475B1 (hr) |
| RU (1) | RU2488397C2 (hr) |
| SI (1) | SI2121138T1 (hr) |
| UA (1) | UA98133C2 (hr) |
| WO (1) | WO2008088233A1 (hr) |
| ZA (1) | ZA200905468B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| US9855277B2 (en) | 2009-07-27 | 2018-01-02 | Bial—Portela & Ca, S.A. | Use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia |
| TR201008460A1 (tr) | 2010-10-15 | 2012-05-21 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Eslikarbazepinin saşe formülasyonları. |
| WO2013032351A1 (en) | 2011-08-26 | 2013-03-07 | BIAL - PORTELA & Cª, S.A. | Treatments involving eslicarbazepine acetate or eslicarbazepine |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| US11883529B2 (en) * | 2020-08-28 | 2024-01-30 | Medtronic, Inc. | Methods of administering anti-epilepsy agents and transport inhibitors to a subject |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB864536A (en) | 1957-11-06 | 1961-04-06 | Sapos S A Lab | ª‡-ethyl-phenylacetylurea |
| GB1028234A (en) | 1964-01-06 | 1966-05-04 | Ici Ltd | New pharmaceutical compositions comprising 5-aminodibenzocycloheptene derivatives |
| CH500196A (de) * | 1969-03-10 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Azepinderivaten |
| CH505101A (de) | 1969-03-31 | 1971-03-31 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Azepinderivaten |
| US3637661A (en) | 1970-03-04 | 1972-01-25 | Ciba Geigy Corp | 10-hydroxy-10 11-dihydro-dibenzazepine derivative |
| CH605791A5 (hr) | 1974-09-27 | 1978-10-13 | Ciba Geigy Ag | |
| EP0011603A1 (de) | 1978-11-10 | 1980-05-28 | Ciba-Geigy Ag | 10-Cyan-5H-dibenz(b,f)azepin-5-carboxamid, Verfahren zu seiner Herstellung und pharmazeutische Präparate, welche diese Verbindung enthalten |
| FI75561C (fi) | 1979-10-30 | 1988-07-11 | Ciba Geigy Ag | Foerfarande foer framstaellning av 5- karbamoyl-10-oxo-10,11-dihydro-5h-dibens/b,f/azepin och daertill noedvaendiga mellanprodukter. |
| CH649080A5 (de) | 1981-04-16 | 1985-04-30 | Ciba Geigy Ag | 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz. |
| AU2929489A (en) | 1987-12-22 | 1989-07-19 | John W. FERKANY | Dextrorphan potentiator for anticonvulsant composition and method |
| EP0435826A1 (de) | 1989-12-27 | 1991-07-03 | Ciba-Geigy Ag | Intravenöse Lösungen für Status Epilepticus |
| US5827819A (en) | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| RU2079304C1 (ru) | 1990-11-08 | 1997-05-20 | Фудзисава Фармасьютикал Ко., Лтд. | Фармацевтическая композиция, обладающая иммуносупрессорной и антимикробной активностями |
| CA2054983A1 (en) | 1990-11-08 | 1992-05-09 | Sotoo Asakura | Suspendible composition and process for preparing the same |
| US5095033A (en) | 1991-03-01 | 1992-03-10 | Laboratoires Biocodex | Method for treating epilepsy |
| FR2699077B1 (fr) | 1992-12-16 | 1995-01-13 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes. |
| FR2702148B1 (fr) | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
| IT1261808B (it) | 1993-07-06 | 1996-06-03 | Impiego di l-carnitina o acido l-carnitine e valproato nel trattamentodei disosrdini convulsivi | |
| US5472714A (en) | 1993-09-08 | 1995-12-05 | Ciba-Geigy Corporation | Double-layered oxcarbazepine tablets |
| CA2575042A1 (en) | 1994-04-28 | 1995-11-09 | Alza Corporation | Effective dosage form for antiepileptic drugs |
| US20030056896A1 (en) | 1995-05-12 | 2003-03-27 | Frank Jao | Effective therapy for epilepsies |
| US5466683A (en) | 1994-08-25 | 1995-11-14 | Teva Pharmaceutical Industries Ltd. | Water-soluble analogs of carbamazepine |
| PT101732B (pt) | 1995-06-30 | 1997-12-31 | Portela & Ca Sa | Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso |
| IT1283594B1 (it) | 1996-04-12 | 1998-04-22 | Trifarma Srl | Derivati della 5h-dibenz- (b,f)-azepin-5-carbossiammide, loro preparazione e uso come sostanze ad azione medicinale |
| DE69724144D1 (de) | 1996-10-19 | 2003-09-18 | Univ Wales Bangor | Verfahren zur herstellung von chemisch reaktiver stärke |
| US5980942A (en) | 1997-01-23 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Zero-order sustained release matrix tablet formulations of carbamazepine |
| US6296873B1 (en) | 1997-01-23 | 2001-10-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Zero-order sustained release delivery system for carbamazephine derivatives |
| CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| IL125244A (en) | 1998-07-07 | 2002-12-01 | Yissum Res Dev Co | Pharmaceutical compositions containing low-melting waxes |
| EP2332580A1 (en) | 1998-12-23 | 2011-06-15 | NeuroTherapeutics Pharma, Inc. | A composition for the treatment of the central nervous system |
| DE60022333T2 (de) | 1999-04-09 | 2006-07-06 | Euro-Celtique S.A. | Natrium kanalblocker zusammensetzungen und deren verwendung |
| AU4307800A (en) | 1999-04-30 | 2000-11-17 | Merab Lomia | New indication for use of antiepileptic agents and medicines |
| US6420369B1 (en) | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
| IL146952A0 (en) | 1999-06-15 | 2002-08-14 | Rhodia Chimie Sa | Sulphonylamides and carboxamides and their use in asymmmetical catalysis |
| US20020147197A1 (en) * | 1999-10-08 | 2002-10-10 | Newman Michael J. | Methods and compositions for enhancing pharmaceutical treatments |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| TWI238062B (en) | 1999-12-01 | 2005-08-21 | Ucb Sa | A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders |
| GB9930058D0 (en) | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| US6191117B1 (en) | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
| WO2002005799A2 (en) | 2000-07-13 | 2002-01-24 | Pharmacia Corporation | Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
| RU2178298C1 (ru) | 2000-12-20 | 2002-01-20 | Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева | Способ лечения больных с резистентными к фармакотерапии формами эпилепсии |
| GB0111566D0 (en) | 2001-05-11 | 2001-07-04 | Portela & Ca Sa | Method for preparation of (s)-(+)-and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azephine-5-carboxamide |
| CN1522140A (zh) | 2001-05-18 | 2004-08-18 | 兰贝克赛实验室有限公司 | 奥卡西平剂型 |
| GB0112812D0 (en) | 2001-05-25 | 2001-07-18 | Portela & Ca Sa | Mthd for preparation of 10, 11-dihydro-10-hydroxy-5H-dibenz/B,F/azepine-5-c arboxamide and 10,11-dihydro-10-oxo-5H-dibenz/B,F/azepine-5-carb oxamide therefrom |
| GB0113663D0 (en) | 2001-06-05 | 2001-07-25 | Novartis Ag | Use of organic compounds |
| RU2236224C2 (ru) | 2001-10-16 | 2004-09-20 | Российский научно-исследовательский нейрохирургический институт им. проф. А.Л. Поленова | Способ лечения эпилепсии |
| WO2003042182A1 (en) | 2001-11-12 | 2003-05-22 | Novartis Ag | Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain |
| PL372393A1 (en) | 2002-02-26 | 2005-07-25 | Ortho-Mcneil Pharmaceutical Inc. | Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and antimigraine agents |
| CA2479672A1 (en) | 2002-03-18 | 2003-10-02 | Roger K. Cady | Preemptive prophylaxis of migraine |
| DE10224170A1 (de) | 2002-05-31 | 2003-12-11 | Desitin Arzneimittel Gmbh | Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung |
| AU2003240654A1 (en) | 2002-05-31 | 2003-12-19 | Desitin Arzneimittel Gmbh | Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release |
| AU2003266965A1 (en) | 2002-08-06 | 2004-02-25 | Novartis Ag | Use of carboxamides for the treatment of tinnitus |
| US20040038874A1 (en) | 2002-08-22 | 2004-02-26 | Osemwota Omoigui | Method of treatment of persistent pain |
| GB0221956D0 (en) | 2002-09-20 | 2002-10-30 | Novartis Ag | Organic compounds |
| GB0223224D0 (en) | 2002-10-07 | 2002-11-13 | Novartis Ag | Organic compounds |
| JP2006509735A (ja) | 2002-10-17 | 2006-03-23 | ノバルティス アクチエンゲゼルシャフト | オクスカルバゼピンまたはその誘導体およびｃｏｘ２インヒビターからなる疼痛処置用医薬組成物 |
| US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| US7259153B2 (en) | 2003-02-03 | 2007-08-21 | Supernus Pharmaceuticals | Drug formulation and delivery using crystalline methylated cyclodextrins |
| GB0303615D0 (en) | 2003-02-17 | 2003-03-19 | Novartis Ag | Use of organic compounds |
| EP1596866A2 (en) | 2003-02-17 | 2005-11-23 | Novartis AG | Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders |
| TW200501962A (en) | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| TW200502222A (en) | 2003-04-02 | 2005-01-16 | Novartis Ag | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
| GB0307860D0 (en) | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
| GB2401605A (en) | 2003-05-12 | 2004-11-17 | Portela & Ca Sa | Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof |
| EP1633400A2 (en) | 2003-05-16 | 2006-03-15 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
| KR20060012628A (ko) | 2003-05-19 | 2006-02-08 | 백스터 인터내셔널 인코포레이티드 | 하나 이상의 표면 변형제로 피복시킨 항경련제 또는면역억제제를 포함하는 고형 입자 |
| BRPI0413920A (pt) | 2003-08-29 | 2006-10-24 | Allergan Inc | emprego de antagonistas seletivos de corrente de sódio persistente para tratar distúrbios neurológicos e dor |
| RU2369393C2 (ru) | 2003-09-03 | 2009-10-10 | Новартис Аг | Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна |
| KR100557093B1 (ko) * | 2003-10-07 | 2006-03-03 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
| US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| CA2553207A1 (en) | 2004-01-13 | 2005-08-04 | Kishore M. Gadde | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
| AR048672A1 (es) | 2004-03-22 | 2006-05-17 | Novartis Ag | Tabletas de desintegracion que comprenden licarbazepina |
| AR048318A1 (es) | 2004-03-22 | 2006-04-19 | Novartis Ag | Formulaciones de matriz orales que comprenden licarbazepina |
| GB2416167A (en) | 2004-07-13 | 2006-01-18 | Portela & Ca Sa | Chiral inversion and esterification of (S)- and (R)-10-hydroxy-dibenzazepine carboxamides |
| GB0425320D0 (en) | 2004-11-17 | 2004-12-22 | Johnson Matthey Plc | Diamines |
| GB2422149A (en) | 2005-01-14 | 2006-07-19 | Portela & Ca Sa | Process for the preparation of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide |
| EP2386303A1 (en) * | 2005-05-06 | 2011-11-16 | Bial-Portela & CA, S.A. | Eslicarbazepine acetate and methods of use |
| MX2007013882A (es) * | 2005-05-06 | 2008-01-28 | Portela & Ca Sa | Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso. |
| US20060252745A1 (en) * | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0515690D0 (en) | 2005-07-29 | 2005-09-07 | Portela & Ca Sa | Asymmetric catalytic reduction |
| GB0603008D0 (en) | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| GB2437078A (en) | 2006-04-11 | 2007-10-17 | Portela & Ca Sa | 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| US8372431B2 (en) | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
| CA2773249A1 (en) | 2009-09-10 | 2011-03-17 | Bial-Portela & C.A., S.A. | Oral suspension formulations of esclicarbazepine acetate |
-
2007
- 2007-01-15 GB GBGB0700773.5A patent/GB0700773D0/en not_active Ceased
-
2008
- 2008-01-14 RU RU2009131075/15A patent/RU2488397C2/ru active
- 2008-01-14 LT LTEP08705172.8T patent/LT2121138T/lt unknown
- 2008-01-14 EP EP16180742.5A patent/EP3222323A1/en not_active Withdrawn
- 2008-01-14 US US12/522,535 patent/US20100048538A1/en not_active Abandoned
- 2008-01-14 NZ NZ578331A patent/NZ578331A/en not_active IP Right Cessation
- 2008-01-14 SI SI200831724A patent/SI2121138T1/sl unknown
- 2008-01-14 MX MX2009007486A patent/MX2009007486A/es active IP Right Grant
- 2008-01-14 AU AU2008205712A patent/AU2008205712B2/en not_active Ceased
- 2008-01-14 ES ES08705172.8T patent/ES2606952T3/es active Active
- 2008-01-14 EP EP08705172.8A patent/EP2121138B1/en not_active Revoked
- 2008-01-14 RS RS20161104A patent/RS55475B1/sr unknown
- 2008-01-14 BR BRPI0806568-3A patent/BRPI0806568A2/pt not_active IP Right Cessation
- 2008-01-14 KR KR1020097016940A patent/KR101519040B1/ko active IP Right Grant
- 2008-01-14 DK DK08705172.8T patent/DK2121138T3/da active
- 2008-01-14 WO PCT/PT2008/000002 patent/WO2008088233A1/en active Application Filing
- 2008-01-14 AR ARP080100164A patent/AR064898A1/es unknown
- 2008-01-14 CA CA2674303A patent/CA2674303C/en active Active
- 2008-01-14 PL PL08705172T patent/PL2121138T3/pl unknown
- 2008-01-14 HU HUE08705172A patent/HUE032467T2/en unknown
- 2008-01-14 PT PT87051728T patent/PT2121138T/pt unknown
- 2008-01-14 CN CNA2008800022840A patent/CN101605571A/zh active Pending
- 2008-01-14 JP JP2009545512A patent/JP2010515727A/ja active Pending
- 2008-01-14 UA UAA200908511A patent/UA98133C2/ru unknown
-
2009
- 2009-07-05 IL IL199697A patent/IL199697A0/en unknown
- 2009-08-05 ZA ZA200905468A patent/ZA200905468B/xx unknown
-
2013
- 2013-12-19 US US14/134,843 patent/US9763954B2/en active Active
-
2016
- 2016-12-02 HR HRP20161619TT patent/HRP20161619T1/hr unknown
- 2016-12-08 CY CY20161101268T patent/CY1118297T1/el unknown
-
2017
- 2017-08-15 US US15/677,165 patent/US20180228812A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161619T1 (hr) | Terapijske primjene eslikarbazepina | |
| HK1221252A1 (zh) | 限制的 肽及含有其的藥物組合物 | |
| IL194550A (en) | Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use | |
| IL197924A (en) | Synthetic peptides, pharmaceutical preparations containing them and their uses | |
| EP3351558A3 (en) | Material and methods for treating or preventing her-3 associated diseases | |
| IL232408A0 (en) | 3303 * a-hla – reduced 1wt peptide and pharmaceutical compound containing it | |
| IL212568A (en) | Annotated 4,1-Diazepan, Pharmaceutical Preparations Containing Them and Their Uses in the Preparation of Medicines for the Treatment of Diseases or Disorders of Mammals | |
| WO2008052185A3 (en) | Materials and methods for the treatment of celiac disease | |
| IL197831A (en) | Human antibodies that bind 4cxcr, preparations containing them and their uses | |
| FI20075794L (fi) | Integroitu prosessi diesel-polttoaineen valmistamiseksi biologisesta materiaalista ja prosessiin liittyvät tuotteet, käyttötavat ja laitteisto | |
| CL2007002214A1 (es) | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp | |
| WO2007111661A3 (en) | Human antibodies specific for gastrin materials and methods | |
| IL197441A (en) | @ Polymer @ and @@ box – a @@ hmgb strains or a wild variety or its active biological components, medicinal preparations containing them and their use in the preparation of drugs for the prevention or treatment of related pathologies to @ hmgbA | |
| AP2010005249A0 (en) | New antibodies specific of the B-amyloid peptides and their uses as diagnostic agents or drugs | |
| HK1140228A1 (en) | Anti fgf23 antibody and pharmaceutical composition comprising the same | |
| IL201730A (en) | History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs | |
| BR112014015331A8 (pt) | materiais hemostáticos e dispositivos com particulados galvânicos | |
| FR2948369B1 (fr) | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique | |
| EP2193789A4 (en) | USE OF 3,5-DIHYDROTOLUENE OR ITS DERIVATIVES IN THE PREPARATION OF MEDICINAL PRODUCTS OR FUNCTIONAL FOOD FOR THE TREATMENT OR PREVENTION OF DEPRESSION | |
| UA105648C2 (uk) | Екструдати з голчатими активними речовинами | |
| WO2008120263A3 (en) | Prokineticins receptors antagonists, derivatives and uses thereof | |
| FR2948370B1 (fr) | Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique | |
| ATE444278T1 (de) | Neue naphtalinderivate, ihr herstellungsverfahren und die pharmazeutischen zusammensetzungen, die sie enthalten | |
| FR2912404B1 (fr) | Derives d'azabicycloalkane,leur preparation et leur application en therapeutique. | |
| ZA201005398B (en) | 15,16-methylene-17-(1'-propenyl)-17,3'-oxidoestra-4-en-3-one derivative,use thereof,and medicament containing said derivative |